{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'advantage in this patient population, and the IC option in this study comprises a group of treatments', 'that are commonly used in clinical practice as monotherapy options.', 'In a phase 2 study of pemetrexed (900 mg/m\u00b2 every 21 days), patients (N = 27) who had 1 prior', 'chemotherapy regimen for recurrent or metastatic cervical cancer had an ORR of 15% and a', 'median os of 7.4 months (Miller 2008). In another phase 2 trial of pemetrexed (500 mg/m\u00b2 every', '21 days) for patients (N = 43) with recurrent or metastatic cervical cancer that had been previously', 'treated with 1 prior chemotherapy regimen in any setting (including concurrent chemoradiation),', 'ORR was 14% and median os was 8 months (Lorusso 2010). The dose and schedule of', 'pemetrexed (500 mg/m\u00b2 IV every 21 days with folic acid and vitamin B12 support) that is used in', 'the current protocol is the same pemetrexed monotherapy regimen that has been approved by the', 'FDA for non-small cell lung cancer (Hanna 2004).', 'Topotecan is an FDA-approved agent for the treatment of cervical cancer when given in', 'combination with cisplatin. Topotecan plus cisplatin, compared to cisplatin alone, improved os', 'for women with stage IVB, recurrent, or persistent cervical cancer that was not amenable to', 'curative treatment with surgery or radiation therapy in GOG179 (Long 2005). A phase 2 study', 'evaluated topotecan monotherapy for patients with recurrent or metastatic cervical cancer who had', 'received no more than 1 prior chemotherapy regimen for metastatic disease. The regimen was', 'topotecan 1.5 mg/m\u00b2 per day for 5 consecutive days of a 21-day cycle. Of 41 evaluable patients,', '34 had received prior chemotherapy, generally including cisplatin. The ORR was 12.5% and the', 'median OS was 6.6 months (Bookman 2000). The 21-day topotecan monotherapy regimen', '(topotecan 1.5 mg/m\u00b2 per day for 5 consecutive days of a 21-day cycle) was subsequently approved', 'in small cell lung cancer (von Pawel 1999) and in ovarian cancer (ten Bokkel Huinink 2004).', 'Topotecan monotherapy is recognized as a palliative option for patients with recurrent or', 'metastatic cervical cancer (NCCN 2017).', 'However, in cervical cancer patients who have received prior platinum-based chemotherapy, the', 'topotecan regimen of 1.5 mg/m\u00b2 per day for 5 consecutive days is associated with unacceptable', 'hematologic toxicity, including 68% and 39% incidence rates of grade 4 neutropenia and grade', '4 thrombocytopenia, respectively (Bookman 2000). Even among patients who had not received', 'prior systemic therapy for recurrent, persistent, or metastatic cervical cancer, the incidence rates', 'of grade 4 neutropenia and grade 4 thrombocytopenia with this regimen were 68% and 18%,', 'respectively (Muderspach 2001). To optimize patient safety, the starting topotecan dose and', 'schedule in this protocol is 1 mg/m\u00b2 per day for 5 consecutive days, which is acceptable in routine', 'clinical practice.', 'A phase 2 study of gemcitabine administered over a 28-day treatment course (800 mg/m\u00b2, 3 weeks', 'on, 1 week rest) enrolled 22 patients who had received 1 prior regimen for metastatic, persistent,', 'or recurrent cervical cancer (Schilder 2005). The ORR was 4.5% and median os was 6.5 months.', 'In the current protocol, the IC regimen for gemcitabine is 1000 mg/m\u00b2 on days 1 and 8 of a 21-day', 'treatment course, which is the FDA-approved dose and schedule for gemcitabine in combination', 'with carboplatin in ovarian cancer (Pfisterer 2006). Gemcitabine also has monotherapy activity in', 'ovarian cancer (Mutch 2007). The FDA approval in ovarian cancer provides toxicity management', 'guidelines that are specific for this dose and schedule of gemcitabine (see Section 8.4.3). Over', '12 weeks, this 21-day treatment course provides similar exposure to gemcitabine (8000 mg) as the', '28-day treatment course in the Schilder study (7200 mg). Gemcitabine monotherapy is', 'Regeneron Pharmaceuticals, Inc.', 'Page 41 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'recommended as a palliative treatment option in recurrent or metastatic cervical cancer', '(NCCN 2017).', 'Vinorelbine monotherapy (30 mg/m\u00b2 days 1 and 8, every 21 days) has been evaluated in two', 'phase 2 studies for women with advanced cervical cancer (recurrent or persistent) who could have', 'received one prior systemic therapy. Among 44 patients with squamous histology, the observed', 'response rate was 13% (5 partial responses, 1 complete response). Grade 3 or 4 neutropenia', 'occurred in 41% of patients (Muggia 2004). Among 22 patients with nonsquamous histology, the', 'observed response rate was 7% (2 partial responses), and grade 3 or 4 neutropenia occurred in 32%', 'of subjects (Muggia 2005). Neither vinorelbine study presented survival data, but the 6 squamous', 'responders received a median of 24 weeks (range, 12 to 30 weeks) of treatment (Muggia 2004),', 'and the 2 nonsquamous responders received 18 weeks of therapy before progression', '(Muggia 2005). The weekly dosing schedule (days 1 and 8, every 21 days) facilitates safe', 'administration for this regimen as regards neutropenia and other potential drug-related AEs.', 'Irinotecan (CPT-11) monotherapy has been studied in several phase 2 clinical trials in advanced', 'cervical cancer (Look 1998) (Takeuchi 1991) (Irvin 1998) (Verschraegen 1997). A phase 2 study', 'evaluated weekly dosing (125 mg/m\u00b2 X 4 weeks, followed by 2 rest weeks) among women with', 'recurrent cervical cancer who could have only received prior chemotherapy as a radiosensitizer', '(Look 1998). Response rate was 13% (6/45 evaluable patients). Survival data was not presented,', 'but duration of response was 8.8 months in 1 patient with complete response and median duration', 'of response was 4.8 months (range, 3.2 to 12+ months) among 5 patients with partial responses.', 'Grade 3 or 4 gastrointestinal toxicity occurred in 39% of patients. In a phase 2 study that evaluated', 'the same regimen in cervical cancer patients who could have received 1 prior chemotherapy for', 'recurrent or metastatic disease, response rate was 21% (9/42) and overall median survival was', '6.4 months. Dose reduction was required in 77% of patients (Verschraegen 1997).', 'In a Japanese phase 2 study of CPT-11 in cervical cancer and ovarian cancer, the observed response', 'rate was 24% (13/55 patients) in the cervical cancer group, including 5 complete responses. Two', 'regimens were used in the study, but no significant differences were observed between the', 'regimens of 100 mg/m\u00b2 weekly dosing or 150 mg/m\u00b2 every 2 week dosing (Takeuchi 1991). The', 'regimen of irinotecan 100 mg/m\u00b2 (weekly for 4 weeks, followed by 2 weeks rest) is approved in', 'Japan for women with recurrent and metastatic cervical cancer. Because the patient population in', 'this protocol will include patients who may have received more than 1 prior line of therapy, this', '100 mg/m\u00b2 weekly dosing regimen (weekly x 4, followed by 2 rest weeks) is selected as the starting', 'dose for this IC option to optimize patient safety.', 'In clinical practice, other possible monotherapy options exist for palliation of advanced cervical', 'cancer, including paclitaxel, bevacizumab, ifosfamide, mitomycin, and 5-fluorouracil', '(NCCN 2017). Paclitaxel or other taxane is not included as an IC chemotherapy option in this', 'protocol because it is anticipated that most study patients will have received prior paclitaxel in the', 'context of prior first-line therapy for recurrent, persistent, or metastatic cervical cancer with', 'cisplatin plus paclitaxel bevacizumab as per the GOG240 regimen (Tewari 2014). Most patients', 'with access to bevacizumab will also have received it as part of the GOG240 regimen. Because', 'no survival advantage has been established in this setting for any monotherapy option, the IC', 'options in this protocol (pemetrexed, topotecan, irinotecan, gemcitabine, and vinorelbine) were', \"selected based on relatively favorable safety profiles and the Gynecologic Oncology Group's\", 'Regeneron Pharmaceuticals, Inc.', 'Page 42 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}